BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34065088)

  • 1. KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.
    West JD; Austin ED; Rizzi EM; Yan L; Tanjore H; Crabtree AL; Moore CS; Muthian G; Carrier EJ; Jacobson DA; Hamid R; Kendall PL; Majka S; Rathinasabapathy A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload.
    Lambert M; Mendes-Ferreira P; Ghigna MR; LeRibeuz H; Adão R; Boet A; Capuano V; Rucker-Martin C; Brás-Silva C; Quarck R; Domergue V; Vachiéry JL; Humbert M; Perros F; Montani D; Antigny F
    Cardiovasc Res; 2021 Nov; 117(12):2474-2488. PubMed ID: 33483721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression.
    Le Ribeuz H; Courboulin A; Ghigna MR; Lambert M; Hautefort A; Humbert M; Montani D; Cohen-Kaminsky S; Perros F; Antigny F
    Respir Res; 2020 Jul; 21(1):186. PubMed ID: 32678044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Heterozygous
    Bohnen MS; Roman-Campos D; Terrenoire C; Jnani J; Sampson KJ; Chung WK; Kass RS
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28889099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of
    Lambert M; Capuano V; Boet A; Tesson L; Bertero T; Nakhleh MK; Remy S; Anegon I; Pechoux C; Hautefort A; Rucker-Martin C; Manoury B; Domergue V; Mercier O; Girerd B; Montani D; Perros F; Humbert M; Antigny F
    Circ Res; 2019 Sep; 125(7):678-695. PubMed ID: 31347976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
    Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
    Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
    Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
    Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCNK3: new gene target for pulmonary hypertension?
    Girerd B; Perros F; Antigny F; Humbert M; Montani D
    Expert Rev Respir Med; 2014 Aug; 8(4):385-7. PubMed ID: 24742047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells.
    Le Ribeuz H; Dumont F; Ruellou G; Lambert M; Balliau T; Quatredeniers M; Girerd B; Cohen-Kaminsky S; Mercier O; Yen-Nicolaÿ S; Humbert M; Montani D; Capuano V; Antigny F
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An homozygous mutation in KCNK3 is associated with an aggressive form of hereditary pulmonary arterial hypertension.
    Navas Tejedor P; Tenorio Castaño J; Palomino Doza J; Arias Lajara P; Gordo Trujillo G; López Meseguer M; Román Broto A; Lapunzina Abadía P; Escribano Subía P
    Clin Genet; 2017 Mar; 91(3):453-457. PubMed ID: 27649371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.
    Cunningham KP; Holden RG; Escribano-Subias PM; Cogolludo A; Veale EL; Mathie A
    J Physiol; 2019 Feb; 597(4):1087-1101. PubMed ID: 30365877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Channelopathy Genes in Pulmonary Arterial Hypertension.
    Welch CL; Chung WK
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of RELM-β prevents hypoxia-induced overproliferation of human pulmonary artery smooth muscle cells by reversing PLC-mediated KCNK3 decline.
    Han L; Song N; Hu X; Zhu A; Wei X; Liu J; Yuan S; Mao W; Chen X
    Life Sci; 2020 Apr; 246():117419. PubMed ID: 32045592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension.
    Navas P; Tenorio J; Quezada CA; Barrios E; Gordo G; Arias P; López Meseguer M; Santos-Lozano A; Palomino Doza J; Lapunzina P; Escribano Subías P
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1011-1019. PubMed ID: 27453251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart.
    Saint-Martin Willer A; Santos-Gomes J; Adão R; Brás-Silva C; Eyries M; Pérez-Vizcaino F; Capuano V; Montani D; Antigny F
    J Physiol; 2023 Sep; 601(17):3717-3737. PubMed ID: 37477289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension.
    Haarman MG; Kerstjens-Frederikse WS; Vissia-Kazemier TR; Breeman KTN; Timens W; Vos YJ; Roofthooft MTR; Hillege HL; Berger RMF
    J Pediatr; 2020 Oct; 225():65-73.e5. PubMed ID: 32502478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.
    Le Ribeuz H; Capuano V; Girerd B; Humbert M; Montani D; Antigny F
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32882918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension.
    Redel-Traub G; Sampson KJ; Kass RS; Bohnen MS
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
    Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
    Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications.
    Olschewski A; Veale EL; Nagy BM; Nagaraj C; Kwapiszewska G; Antigny F; Lambert M; Humbert M; Czirják G; Enyedi P; Mathie A
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.